8-K: Cibus Inc. Releases Unaudited Pro Forma Combined Financials Following Merger

Cibus Inc. has released unaudited pro forma combined financial statements for the year ended December 31, 2023, following its merger with Cibus Global, LLC.

Summary

• Cibus Inc. completed its business combination with Cibus Global, LLC on May 31, 2023.
• The pro forma combined statement of operations for the year ended December 31, 2023, combines the historical results of Cibus Inc. for the full year with Cibus Global's results for the five months ended May 31, 2023.
• The merger was accounted for as a business combination, with Cibus Inc. considered the acquirer of Cibus Global.
• The total revenue for the combined entity was $2.257 million.
• The combined operating expenses totaled $351.118 million, including a significant goodwill and intangible asset impairment of $249.419 million.
• The net loss attributable to the combined company was $295.773 million.
• The basic and diluted net loss per share of Class A common stock was $25.95.
• The weighted average shares of Class A common stock outstanding was 25,879,506.
• The purchase price for the acquisition was approximately $634.8 million, primarily in the form of Cibus Inc. stock.

Sentiment

Score: 3

Explanation: The document reveals a significant net loss and substantial impairment charges, indicating a weak financial position post-merger. The pro forma nature of the financials and the lack of positive outlook contribute to a negative sentiment.

Positives

• The merger provides a combined financial view of the two entities.
• The document provides a detailed breakdown of the purchase price allocation.

Negatives

• The combined company experienced a significant net loss of $295.773 million.
• There was a substantial goodwill and intangible asset impairment of $249.419 million.
• The basic and diluted net loss per share was $25.95, indicating a significant loss per share.
• The pro forma financial information is based on assumptions and may not reflect actual future results.

Risks

• The pro forma financial information is based on preliminary estimates and may change significantly.
• The actual amounts recorded as of the completion of the Mergers may differ materially from the information presented.
• The company is still in the process of finalizing the purchase price allocation, which may lead to revisions.
• The unaudited pro forma combined financial information does not include the impact of any cost or other operating synergies that may result from the Mergers or any related restructuring costs that may be contemplated.

Future Outlook

The unaudited pro forma combined financial information should not be relied upon as being indicative of the historical results that would have been achieved had the companies always been combined or the future results that the Combined Company will experience.

Industry Context

This merger is part of a broader trend of consolidation in the biotechnology and agricultural technology sectors, where companies seek to combine resources and expertise to accelerate innovation and market penetration.

Comparison to Industry Standards

• The significant net loss and impairment charges are concerning when compared to industry leaders in the agricultural biotechnology space, such as Corteva and Bayer Crop Science, which typically report positive earnings.
• The pro forma revenue of $2.257 million is very low compared to the revenue of established players in the industry, indicating that Cibus is still in an early stage of commercialization.
• The high operating expenses, particularly the research and development costs, are typical for companies in this sector, but the magnitude of the impairment suggests potential issues with the valuation of acquired assets.

Related Party Transactions

• The document mentions a royalty liability interest expense related to related parties of $24.610 million.

Stakeholder Impact

• Shareholders will be negatively impacted by the significant net loss and the decrease in value of the company.
• Employees may be concerned about the financial stability of the company.
• Customers and suppliers may be concerned about the long-term viability of the company.

Next Steps

• The company will finalize the purchase price allocation during the 12-month period following the acquisition date.
• The company will continue to develop its products, which are currently in various stages of development.

Key Dates

Keywords

Merger, Pro Forma, Financial Statements, Business Combination, Acquisition, Cibus Global, Cibus Inc., Impairment, Net Loss, Reverse Stock Split